# US 2008/0306080 A1 · Neutrophilia inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306080 A1
- Document ID: US20080306080A1
- Status: Published application
- Kind: A1
- Application number: 12/188,638
- Filed: 2008-08-08
- Published: 2008-12-11
- Earliest claimed: 2003-12-26
- Assignees: Nissan Chemical Industries, Ltd.; Taisho Pharmaceutical Co., Ltd.
- Inventors: Takehisa Iwama; Nobutomo Tsuruzoe
- Web page: https://patentgrep.com/patent/US20080306080A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61P 5/38: of the suprarenal hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

To provide an antineutrophilia agent effective for treatment of development and progress of acute infections, collagen diseases (chronic rheumatoid arthritis, Wegener's granulomatosis and Behcet's disease), chronic obstructive pulmonary disease (COPD), chronic bronchitis, pulmonary emphysema, small airway disease, gout, Cushing's syndrome, myelofibrosis, neoplastic neutrophilia, polycythemia vera and diseases caused by administration of steroid drugs. An antineutrophilia agent containing a 3(2H)-pyridazinone compound represented by the formula (I) or a pharmaceutically acceptable salt thereof [wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 is alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene which may be substituted with a hydroxyl group].

## Claims

### Claim at position 1

1-5. (canceled)

### Claim 6

A method of treating neutrophilia in a mammalian subject in need of such treatment, the method comprising administering a 3(2H)-pyridazinone compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to the subject to treat neutrophilia:
wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene or a C1-8 alkylene substituted with a hydroxyl group.

### Claim 7 (depends on 6)

The method according to claim 6, wherein in the formula (I), R1 and R2 are hydrogen atoms, R3 is a hydrogen atom or a C1-4 alkyl group, X is a halogen atom, Y is a halogen atom or a hydrogen atom, and A is a C1-5 alkylene or a C1-8 alkylene substituted with a hydroxyl group.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the compound represented by the formula (I) is 4-bromo-6-[3-(4-chlorophenyl)propoxy-5-(3-pyridylmethylamino)-3(2H)-pyridazinone or 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the pharmaceutically acceptable salt is an organic acid salt or an inorganic acid salt.

### Claim 10

A method for treating chronic obstructive pulmonary disease in a mammalian subject in need of such treatment, the method comprising administering a 3(2H)-pyridazinone compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to the subject to treat chronic obstructive pulmonary disease:
wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene or a C1-8 alkylene substituted with a hydroxyl group.

### Claim 11 (depends on 10)

The method according to claim 10, wherein in the formula (I), R1 and R2 are hydrogen atoms, R3 is a hydrogen atom or a C1-4 alkyl group, X is a halogen atom, Y is a halogen atom or a hydrogen atom, and A is a C1-5 alkylene or a C1-8 alkylene substituted with a hydroxyl group.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the compound represented by the formula (I) is 4-bromo-6-[3-(4-chlorophenyl)propoxy-5-(3-pyridylmethylamino)-3(2H)-pyridazinone or 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the pharmaceutically acceptable salt is an organic acid salt or an inorganic acid salt.
